Report cover image

Alzheimer’s Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 16, 2024
Length 196 Pages
SKU # IRE18418252

Description

Alzheimer’s Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2024-2030


The Alzheimer’s Therapeutics Market size was estimated at USD 6.14 billion in 2023 and expected to reach USD 6.66 billion in 2024, at a CAGR 8.63% to reach USD 10.96 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alzheimer’s Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alzheimer’s Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer’s Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer’s Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class

Cholinesterase Inhibitors
  • NMDA [N-methyl-D-aspartate] Receptor Antagonist
  • Type

    Medication

    Cholinesterase inhibitors
  • Donepezil
  • Galantamine
  • Rivastigmine
  • NMDA Receptor Antagonist
  • Distribution

    Online Pharmacies
  • Retail Pharmacies
  • Region

    Americas

    Argentina
  • Brazil
  • Canada
  • Mexico
  • United States

    California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific

    Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa

    Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom
    The report offers valuable insights on the following aspects:

    1. Market Penetration: It presents comprehensive information on the market provided by key players.
    2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
    3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
    4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
    5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
    The report addresses key questions such as:

    1. What is the market size and forecast of the Alzheimer’s Therapeutics Market?
    2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alzheimer’s Therapeutics Market?
    3. What are the technology trends and regulatory frameworks in the Alzheimer’s Therapeutics Market?
    4. What is the market share of the leading vendors in the Alzheimer’s Therapeutics Market?
    5. Which modes and strategic moves are suitable for entering the Alzheimer’s Therapeutics Market?


    Note: PDF & Excel + Online Access - 1 Year

    • Table of Contents

    196 Pages
    1. Preface
    1.1. Objectives of the Study
    1.2. Market Segmentation & Coverage
    1.3. Years Considered for the Study
    1.4. Currency & Pricing
    1.5. Language
    1.6. Limitations
    1.7. Assumptions
    1.8. Stakeholders
    2. Research Methodology
    2.1. Define: Research Objective
    2.2. Determine: Research Design
    2.3. Prepare: Research Instrument
    2.4. Collect: Data Source
    2.5. Analyze: Data Interpretation
    2.6. Formulate: Data Verification
    2.7. Publish: Research Report
    2.8. Repeat: Report Update
    3. Executive Summary
    4. Market Overview
    4.1. Introduction
    4.2. Alzheimer’s Therapeutics Market, by Region
    5. Market Insights
    5.1. Market Dynamics
    5.1.1. Drivers
    5.1.1.1. Rising incidences of Alzheimer’s among population
    5.1.1.2. Growing development and availability of pipeline drugs
    5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer’s
    5.1.2. Restraints
    5.1.2.1. Capital intensive treatment for Alzheimer’s
    5.1.3. Opportunities
    5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
    5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    5.1.4. Challenges
    5.1.4.1. Stringent drug approval processes
    5.2. Market Segmentation Analysis
    5.3. Market Trend Analysis
    5.4. Cumulative Impact of High Inflation
    5.5. Porter’s Five Forces Analysis
    5.5.1. Threat of New Entrants
    5.5.2. Threat of Substitutes
    5.5.3. Bargaining Power of Customers
    5.5.4. Bargaining Power of Suppliers
    5.5.5. Industry Rivalry
    5.6. Value Chain & Critical Path Analysis
    5.7. Regulatory Framework
    6. Alzheimer’s Therapeutics Market, by Drug Class
    6.1. Introduction
    6.2. Cholinesterase Inhibitors
    6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist
    7. Alzheimer’s Therapeutics Market, by Type
    7.1. Introduction
    7.2. Medication
    7.3.1. Cholinesterase inhibitors
    7.3.2. Donepezil
    7.3.3. Galantamine
    7.3.4. Rivastigmine
    7.3. NMDA Receptor Antagonist
    8. Alzheimer’s Therapeutics Market, by Distribution
    8.1. Introduction
    8.2. Online Pharmacies
    8.3. Retail Pharmacies
    9. Americas Alzheimer’s Therapeutics Market
    9.1. Introduction
    9.2. Argentina
    9.3. Brazil
    9.4. Canada
    9.5. Mexico
    9.6. United States
    10. Asia-Pacific Alzheimer’s Therapeutics Market
    10.1. Introduction
    10.2. Australia
    10.3. China
    10.4. India
    10.5. Indonesia
    10.6. Japan
    10.7. Malaysia
    10.8. Philippines
    10.9. Singapore
    10.10. South Korea
    10.11. Taiwan
    10.12. Thailand
    10.13. Vietnam
    11. Europe, Middle East & Africa Alzheimer’s Therapeutics Market
    11.1. Introduction
    11.2. Denmark
    11.3. Egypt
    11.4. Finland
    11.5. France
    11.6. Germany
    11.7. Israel
    11.8. Italy
    11.9. Netherlands
    11.10. Nigeria
    11.11. Norway
    11.12. Poland
    11.13. Qatar
    11.14. Russia
    11.15. Saudi Arabia
    11.16. South Africa
    11.17. Spain
    11.18. Sweden
    11.19. Switzerland
    11.20. Turkey
    11.21. United Arab Emirates
    11.22. United Kingdom
    12. Competitive Landscape
    12.1. FPNV Positioning Matrix
    12.2. Market Share Analysis, By Key Player
    12.3. Competitive Scenario Analysis, By Key Player
    12.3.1. New Product Launch & Enhancement
    12.3.1.1. The Next Phase of Alzheimer’s Therapeutics with Alzstatin ACD680
    12.3.1.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer’s
    13. Competitive Portfolio
    13.1. Key Company Profiles
    13.1.1. AbbVie Inc.
    13.1.2. AC Immune SA
    13.1.3. Acadia Pharmaceuticals Inc.
    13.1.4. Alnylam Pharmaceuticals, Inc.
    13.1.5. AlzeCure Pharma AB
    13.1.6. Alzheon, Inc.
    13.1.7. AstraZeneca PLC
    13.1.8. Biogen Inc.
    13.1.9. Cassava Sciences, Inc.
    13.1.10. Cognition Therapeutics, Inc.
    13.1.11. Corium, Inc.
    13.1.12. Eisai Co., Ltd.
    13.1.13. Eli Lilly and Company
    13.1.14. F. Hoffmann-La Roche Ltd.
    13.1.15. Grifols S.A.
    13.1.16. H. Lundbeck A/S
    13.1.17. Luye Pharma Group Ltd.
    13.1.18. Merz Pharma GmbH & Co. KGaA
    13.1.19. NeuroVision Imaging, Inc.
    13.1.20. Novartis AG
    13.1.21. Oryzon Genomics, S.A.
    13.1.22. Pfizer, Inc.
    13.1.23. Siemens Healthcare GmbH
    13.1.24. Synaptogenix, Inc.
    13.1.25. TauRx Pharmaceuticals Ltd.
    13.1.26. VTV Therapeutics
    13.2. Key Product Portfolio
    14. Appendix
    14.1. Discussion Guide
    14.2. License & Pricing
    FIGURE 1. ALZHEIMER’S THERAPEUTICS MARKET RESEARCH PROCESS
    FIGURE 2. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2023 VS 2030
    FIGURE 3. ALZHEIMER’S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
    FIGURE 4. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
    FIGURE 5. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 6. ALZHEIMER’S THERAPEUTICS MARKET DYNAMICS
    FIGURE 7. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
    FIGURE 8. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 9. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
    FIGURE 10. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 11. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
    FIGURE 12. ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 13. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 14. AMERICAS ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 15. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
    FIGURE 16. UNITED STATES ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 17. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 18. ASIA-PACIFIC ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
    FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER’S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
    FIGURE 21. ALZHEIMER’S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
    FIGURE 22. ALZHEIMER’S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us